#South Korea #Seoul #LabConnect #Clinical Trials #GCCL

GCCL and LabConnect Join Forces to Advance Global Clinical Trials

On October 12, 2026, GCCL, a premier central laboratory for clinical trials based in South Korea, and LabConnect, a global provider of central laboratory services, officially signed a memorandum of understanding (MOU) aimed at enhancing their global collaboration in clinical studies. This partnership is built upon over 20 years of prior collaboration and aims to boost efficiency in conducting international clinical trial projects by integrating the regional capabilities and expertise of both companies across North America and the Asia-Pacific (APAC) region.

The signing ceremony took place at GCCL's headquarters, attended by key representatives from both organizations. Included among them were Kwan-goo Cho, CEO of GCCL, and Jeff Mayhew, founder and strategic advisor of LabConnect. During the event, they shared insights into their core services and future visions, and addressed key collaborative initiatives such as:
1. Identifying potential clients and supporting regional sales efforts.
2. Integrating global clinical trials with central laboratory services.
3. Collaborating on project management and customer communications.
4. Developing joint marketing strategies and exploring new business opportunities.

Under this MOU, GCCL and LabConnect are set to establish a cooperative structure that leverages their respective regional strengths and partnerships. They also plan to promote joint sales and marketing initiatives while implementing unified systems and processes for customer inquiries and project management.

Jeff Mayhew commented on the collaboration, stating, “By partnering with GCCL, we anticipate simplifying the execution and coordination of complex studies both in South Korea and across the APAC region. The union of GCCL’s laboratory and logistics expertise with our global network of clinical laboratories and specialized labs enhances our ability to offer clients better-coordinated execution of multi-regional studies.”

Meanwhile, Kwan-goo Cho emphasized the importance of this MOU, stating that it marks the beginning of a synergy between GCCL's clinical trial execution capabilities in the APAC region and LabConnect's broad global network of clinical and specialized laboratories. He articulated the vision of forming a practical cooperative structure encompassing joint distribution, project execution, and customer management to augment their global clinical trial business.

Insights on LabConnect and GCCL

LabConnect offers comprehensive central laboratory services and solutions for managing clinical trial samples, covering the entire sample lifecycle, from biomarker strategy and customized sample collection kit assembly to analysis, storage, and delivery of submission-ready data. The firm combines scientific and operational expertise with its global network, providing integrated data management services and supporting routine and specialized testing within complex international studies. LabConnect is dedicated to helping pharmaceutical, biotechnology, and contract research organizations mitigate risks, increase predictability, and extract meaningful insights from every sample.

GCCL, a subsidiary of GC Group, is recognized as a leading provider of sample analysis for clinical trials, offering an integrated laboratory solution that combines central labs, bioanalytical laboratories, and BSL-3 labs within a unified system. GCCL delivers tailored, precise, and efficient analytical services across all phases of clinical trials, solidifying its reputation as a reliable partner in drug development. Utilizing advanced platforms and LIMS, GCCL supports partners throughout Asia and beyond with customized solutions compliant with regulatory standards. Recently, the company received the 2025 Best Practices Customer Value Leadership Award from Frost & Sullivan, acknowledging its premier position in clinical trial sample analysis in the APAC region.

With this impressive collaboration, both GCCL and LabConnect are poised to enhance the landscape of clinical trials worldwide, ensuring the delivery of high-quality and timely results to their clients.